Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Castillo was born in Peru, received his medical degree at the Universidad Autonoma Metropolitana in Mexico City, and completed his Internal Medicine, and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School, Senior Physician at the Dana-Farber Cancer Institute, and Clinical Director of the Bing Center for Waldenström Macroglobulinemia.

Dr. Castillo is the principal investigator in innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Research grants were obtained from Abbvie and Pharmacyclics to study the combination of ibrutinib and venetoclax in previously untreated Waldenström Macroglobulinemia (DFCI 19-651), AstraZeneca to investigate the combination of acalabrutinib and rituximab in patients with anti-MAG neuropathy (DFCI 21-439), and LOXO to investigate the combination of pirtobrutinib and venetoclax in patients with previously treated Waldenström Macroglobulinemia (DFCI 22-611). Funding from the Kaplan Family and the International Waldenström Macroglobulinemia Foundation was secured to create the Waldenström Macroglobulinemia Clinical Trial Network. Additional funding was secured from the Bell Family to create a research fellowship position to focus on translational, transformative basic research at the Bing Center for Waldenström Macroglobulinemia laboratory.

He has authored over 300 peer-reviewed articles. Highlights include the results of a prospective study on venetoclax in patients with previously treated Waldenström Macroglobulinemia, the long-term report on ibrutinib in previously untreated Waldenström Macroglobulinemia, and the initial report of a prospective study investigating ibrutinib in previously untreated Waldenström Macroglobulinemia published in the Journal of Clinical Oncology, the consensus for treating patients with Waldenström Macroglobulinemia from the 10th International Workshop for Waldenström Macroglobulinemia published in Lancet Haematology, a retrospective experience with ibrutinib in Bing-Neel syndrome and the results of a prospective study evaluating ibrutinib and ulocuplumab in patients with Waldenström Macroglobulinemia and CXCR4 mutations published in Blood, and reviews on the management of monoclonal gammopathy of renal and neurological significance and the management of Waldenström macroglobulinemia with BTK inhibitors published in the American Journal of Hematology.

Dr. Castillo has been a speaker at the Educational Sessions at the American Society of Hematology Annual Meeting, the American Society of Clinical Oncology Annual Meeting, the International Workshop for Waldenström Macroglobulinemia, the International Myeloma Workshop, and the Bruce Waterfall Memorial Lecture in Waldenström Macroglobulinemia at the Lymphoma & Myeloma Congress in New York. He has also lectured at the Leukemia, Lymphoma & Myeloma Congress, the Society of Hematology and Oncology (SOHO), the NCCN Hematologic Malignancies Annual Congress, and the Annual Chemotherapy Symposium.

Dr. Castillo has been awarded the Innovation Award by the Dana-Farber Cancer Institute, and the Robert A. Kyle Award by the International Workshop for Waldenström Macroglobulinemia.

Please feel free to visit JorgeJCastillo.com where you will find more specific information on the Bing Center Clinic, as well as a more specific list of my technical publications.